Our results confirm a previous case report in which a sharp rise in plasma atrial natriuretic factor was recorded immediately after pericardiocentesis.3 A similar twofold to threefold increase was also described after pericardiectomy in a patient with chronic constrictive pericarditis.4 These findings are in strong contrast to other conditions, such as left ventricular failure, in which cardiac filling pressures are correlated with circulating concentrations of atrial natriuretic factor.5 Clinical deterioration is associated with a further increase in peptide concentrations, while treatments which lower cardiac filling pressures also lower plasma atrial natriuretic factor values.' Our findings suggest that raised atrial pressure does not directly stimulate the release of atrial natriuretic factor. 
Patients and methods
Ten agromegalic patients (mean age 45, mean duration 11 years) were treated with octreotide. All 10 had undergone surgery or irradiation, and eight had received bromocriptine (four ofwhom were intolerant). All had a baseline 24 hour profile of growth hormone measured every two hours, followed by a 75 g oral glucose tolerance test starting at 1000. The initial dose of octreotide was 100 Fg subcutaneously at 0800, 1600, and 2400 for one month and was increased at monthly intervals by 300 Mean serum growth hormone fell from 36 (SE 10) mU/l at the onset of the study to 8 (1) mU/l and 8 (2) mU/l (n=8, p<0 05) after six and 12 months respectively. Of three patients with normal glucose tolerance initially, one remained normal, one developed impaired glucose tolerance, and one became diabetic (by World Health Organisation criteria). Of four patients who had impaired glucose tolerance initially, two remained unchanged, one developed diabetes, and the other returned to normal glucose tolerance. One of the seven patients who had normal baseline ultrasonic appearances of the gall bladder had developed multiple small gall stones after six months of treatment, and another two developed similar findings after one year (fig) . One patient did not have an initial examination but after four months of therapy had four gall stones, which remained unchanged at each assessment.
Comment
Octreotide successfully lowered growth hormone concentrations and was generally well tolerated. It had a heterogeneous effect on lucose tolerance. Three patients became more glucose intolerant, three showed no change, and one had improved glucose tolerance. As growth hormone induces insulin resistance and octreotide reduces both insulin and growth hormone secretion the relative change of each will influence glucose tolerance.3
The high incidence of new gall stones found in our prospective study is a cause for concern. Previously w Ultrasound scans ofa patient showing(left) a normal gall bladder before treatment and (right) multiple tiny gall stones after 12 months' treatment. These were mobile on real time scans and showed acoustic shadowing there have been only isolated reports of gall stones occurring during octreotide treatment.' Gall bladder contraction and cholecystokinin secretion in response to food are almost abolished by its administration4 and may contribute to stone formation. The high incidence of gall stones might have been due to the higher doses of the drug which we used. None of our patients had symptoms from the gall stones, and the correct management of the stones remains problematical.5 While further prospective studies of the incidence of gall stones during octreotide treatment are awaited we recommend the use of the smallest effective dose of octreotide. 
